Arch Biopartners Inc. ARCH.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 100.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 100.00% | -- |
| Cost of Revenue | 90.23% | 30.20% | 393.42% | -135.12% | -76.02% |
| Gross Profit | -603.83% | -30.20% | -3,316.07% | 118.24% | 109.05% |
| SG&A Expenses | -13.77% | -31.62% | 257.70% | 18.44% | -15.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.70% | -15.81% | 295.06% | -73.30% | -53.30% |
| Operating Income | -115.38% | 15.81% | -478.84% | 82.80% | 74.05% |
| Income Before Tax | -95.95% | 1.17% | -276.09% | 75.80% | 72.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -95.95% | 1.17% | -276.09% | 75.80% | 72.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -95.95% | 1.17% | -276.09% | 75.80% | 72.90% |
| EBIT | -115.38% | 15.81% | -478.84% | 82.80% | 74.05% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -96.15% | 3.39% | -267.39% | 77.44% | 74.76% |
| Normalized Basic EPS | -88.24% | 5.41% | -265.52% | 77.11% | 73.44% |
| EPS Diluted | -96.15% | 3.39% | -267.39% | 77.44% | 74.76% |
| Normalized Diluted EPS | -88.24% | 5.41% | -265.52% | 77.11% | 73.44% |
| Average Basic Shares Outstanding | 2.75% | 2.25% | 1.79% | 7.79% | 5.34% |
| Average Diluted Shares Outstanding | 2.75% | 2.25% | 1.79% | 7.79% | 5.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |